MediNavi AG: Embracing the New Year with Confidence

A Bright Outlook for 2024

Frankfurt am Main, 24.01.2024 (pta024/24.01.2024/16:05 UTC+1)

Dear Shareholders,

as we embark on this new year, we extend our warmest wishes to each and every one of you. Your unwavering support and trust in MediNavi have been instrumental to our journey thus far, and we're excited to share our vision and expectations for 2024, which we believe hold the promise of a bright and prosperous future.

Reflecting on Our Progress in 2023:

Before we delve into our plans for the year ahead, let's take a moment to reflect on the achievements and milestones we reached in 2023. It was a year of tremendous growth and transformation for MediNavi. We expanded our product portfolio, ventured into new markets, solidified our position in existing ones through acquisition, and forged strategic partnerships that have been contributory to our success.

Our accomplishments in 2023 were made possible by the dedication, creativity, and tireless efforts of the exceptional members of our team. Their unwavering commitment to excellence continues to drive our growth and success, and we extend our heartfelt gratitude to them.

A Promising Year Ahead:

We've crossed the threshold of 2024 with a profound sense of optimism. There are several reasons why we believe this year will be one of remarkable progress and achievement:

1. Innovative Products and Services: Our commitment to innovation remains at the forefront of our strategy. In 2024, we're poised to launch a range of groundbreaking products and services that won't only meet but exceed the ever-evolving needs and expectations of our customers. Our dedication to research and development ensures that we stay ahead of the curve in our industry.
2. Market Expansion: To fuel our growth, we'll be exploring new markets and regions. This expansion won't only diversify our revenue streams but also expose us to exciting opportunities for further growth. We'll leverage our industry expertise to make strategic inroads into these markets.
3. Sustainability Initiatives: Sustainability is not just a buzzword to us; it's a core commitment. In 2024, we'll launch several sustainability initiatives aimed at reducing our environmental footprint and contributing to a more sustainable future. We recognize our responsibility and are dedicated to making a positive impact.
4. Growth: The Company's growth strategy in Europe encompasses a three-pronged approach: fostering internal development for steady organic expansion though opening new markets, strategically acquiring complementary businesses for rapid market penetration, and forging industrial partnerships to leverage external expertise and resources. The Company is currently working on different opportunities.
5. Resilience and Adaptability: The business landscape is ever-changing, and our ability to adapt to these changes has been a cornerstone of our success. We remain agile and resilient, ready to pivot when needed and seize emerging opportunities while navigating challenges effectively.

A Shared Vision:

At MediNavi, we firmly believe that our success is a collective effort. It's a result of the combined dedication and hard work of our team, the support of our partners, and the trust and confidence of our shareholders. Together, we've built a company that is poised for greatness, and together, we'll continue to write the next chapters of our success story in 2024 and beyond.

As we move forward, we invite you to join us on this exciting journey. Your feedback, insights, and perspectives are invaluable to us. We're committed to transparency and open communication and welcome your active participation.

Kind regards,

The Board of Directors, MediNavi AG

About Nordic Swan Pharma Group ApS

Nordic Swan Pharma Group is a pharmaceutical company specialized in medicinal cannabis, cannabinoids, and CBD-infused skincare products and supplements. Nordic Swan Pharma Group is investing in the Medical Cannabis Industry across Europe with a dedication and vision to improve individuals' quality of life and specializing in the development and manufacturing of nutraceuticals, supplements, and skincare products containing cannabinoids and other naturally powerful ingredients which is been sold via webshop across Europa and Scandinavia.

About MediNavi AG

Based in Frankfurt, Germany, MediNavi AG is a holding company that wholly owns Nordic Swan Pharma Group ApS. Medinavi is specialized incannabinoids, and CBD-infused skincare products and supplements. Our vision is to improve individuals' quality of life and specializing in the development and manufacturing of nutraceuticals, supplements, and skincare products containing cannabinoids and other naturally powerful ingredients that are sold via web shops throughout Europa and Scandinavia.

(end)

Emitter:	MediNavi AG Hausener Weg 29 60489 Frankfurt am Main Germany
Contact Person:	Dr. Anna Wohlthat
E-Mail:	anna@wohlthat.ag
Website:	www.medinavi.de
ISIN(s):	DE000A3MQRE9 (Share)
Stock Exchange(s):	Free Market in Hamburg (High Risk Market)